UK markets open in 4 hours 12 minutes
  • NIKKEI 225

    28,574.15
    +240.63 (+0.85%)
     
  • HANG SENG

    24,277.81
    +59.78 (+0.25%)
     
  • CRUDE OIL

    84.97
    +1.15 (+1.37%)
     
  • GOLD FUTURES

    1,816.90
    +0.40 (+0.02%)
     
  • DOW

    35,911.81
    -201.79 (-0.56%)
     
  • BTC-GBP

    30,884.98
    -673.36 (-2.13%)
     
  • CMC Crypto 200

    1,010.52
    -15.21 (-1.48%)
     
  • ^IXIC

    14,893.75
    +86.95 (+0.59%)
     
  • ^FTAS

    4,292.58
    +35.99 (+0.85%)
     

BioNTech to Present at the 40th Annual J.P. Morgan Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

MAINZ, Germany, December 27, 2021BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that CEO and Co-founder Ugur Sahin, M.D., will present a corporate overview and update at the virtual 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 9:45 am ET.

A live webcast of the presentation will be available via the “Events & Presentations” page in the Investor Relations section on the Company’s website at https://biontech.de/. The replay of the webcast will be archived on the Company’s website for 30 days following the conference.

About BioNTech
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.de.

Media Relations
Jasmina Alatovic
+49 (0)6131 9084 1513
Media@biontech.de

Investor Relations
Sylke Maas, Ph.D.
+49 (0)6131 9084 1074
Investors@biontech.de


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting